GH1 and metabolic syndrome: Despite favorable changes in some metabolic abnormalities seen in several controlled studies of patients with growth hormone deficiency during GH replacement therapy, prevalence of the metabolic syndrome (using a composite measure for the metabolic syndrome as a major outcome) remained unchanged or even increased during long-term GH replacement therapy [97,98,99].